Clinical Trials Directory

Trials / Conditions / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity

Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity

11 registered clinical trials studyying Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity.

StatusTrialSponsorPhase
Completed18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis
NCT01806675
Sanjiv Sam GambhirPhase 1 / Phase 2
CompletedCetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cance
NCT01637194
Fox Chase Cancer CenterPhase 1
CompletedBevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Pri
NCT00492089
National Cancer Institute (NCI)Phase 2
CompletedErlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec
NCT00397384
National Cancer Institute (NCI)Phase 1
CompletedPhotodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck
NCT00470496
Roswell Park Cancer InstitutePhase 1
CompletedErlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne
NCT00101348
National Cancer Institute (NCI)Phase 1 / Phase 2
CompletedAlvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00089362
National Cancer Institute (NCI)Phase 1
CompletedGefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can
NCT00068497
National Cancer Institute (NCI)N/A
CompletedErlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
NCT00030498
National Cancer Institute (NCI)Phase 1
Completed7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid
NCT00031681
National Cancer Institute (NCI)Phase 1
CompletedBevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and
NCT00023959
National Cancer Institute (NCI)Phase 1